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For patients with primary, localized gastrointestinal stromal tumors (GIST), surgery
with complete excision is the treatment of choice.1 However, more than half of
patients experience tumor recurrence during the course of their disease,2 and
complete resection can be achieved only in less than half of these patients who had
recurrence of the tumors. Recently, imatinib has been applied in the treatment of
unresectable or recurrent GISTs, resulting in improved patient survival. However,
long-term results of imatinib in metastatic GIST as well as its complete response
during treatment are very rare.3-6 Moreover, the results of cytoreductive surgery in
patients with far advanced or metastatic GISTs who are treated with imatinib are
also rare. Herein, we report two patients who have experienced long-term survival
with recurrent GIST after receiving cytoreductive surgery with imatinib therapy. 
Case 1
A 49-year-old man came to the emergency center presenting with epigastric pain
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and melena in April 2002. Esophagogastroduodenoscopy
showed a centrally ulcerative huge mass with bleeding in
the superior wall of the duodenal 1st portion. A biopsy was
performed, and the mass was confirmed as a spindle cell
type GIST with strong c-kit immunoreactivity. A CT scan
revealed a 2.5 cm sized solid mass lesion in the duodenum,
and a 1.3 cm low-density lesion in the right lobe of the liver
(Fig. 1). A liver MRI showed a 1.6 cm sized solitary
metastatic nodular lesion in liver segment V. The patient
received a distal subtotal gastrectomy with gastroduodeno-
stomy and a negative microscopic surgical margin. The
patient simultaneously received intraoperative radiofreq-
uency ablation for the hepatic lesion. Pathological analysis
revealed a 3×2 cm sized, well-circumscribed duodenal
GIST with an ulcerative surface, and mitotic counts higher
than 5 per 50 high-powered fields (HPF) (Fig. 2).
Four months later, a follow-up CT scan was performed,
and a new 0.9 cm sized small metastatic lesion was visual-
ized in segment VII of the liver (Fig. 3). Radiofrequency
ablation was performed again for the lesion, and the patient
was then treated with imatinib mesylate (STI 571, Gleevec®
or GlivecTM; Novartis Pharmaceuticals, Basel, Switzerland)
at a dosage of 400 mg daily. The patient regularly visited
our clinic for CT scanning and esophagogastroduodenoscopy.
As of April 2007, he was taking the imatinib mesylate, and
there was no evidence of tumor recurrence. 
Case 2
A 56 year-old man was referred to our hospital in September
2001. He had previously received a laparoscopic assisted
segmental resection of distal ileum due to a malignant GIST
at another hospital in March 2001. The GIST was 6×5 cm
in size and attached to the parietal peritoneum. The parietal
peritoneum was also excised along with the mass. In April
2001, the patient received a CT scan because of vague abdo-
minal pain. The scan revealed a 3 cm sized solid lesion in
the left lateral segment of the liver, and multiple scattered
nodular masses in the peritoneal space (Fig. 4). He was
diagnosed with recurrence of malignant GIST with peritoneal
seeding and hepatic metastasis, and was referred to our
hospital for further treatment. 
During surgery, several ovoid to spherical congregated
masses were found to be attached to the serosal surface of
ascending colon and the mesentery of small bowel, omen-
tum, and peritoneal surface. The masses showed smooth,
glistening, and multinodular external surfaces, with the
diameter of the largest mass at 5 cm. In addition, a 3.5 cm
sized mass was found also in the left lateral segment of the
liver. Cytoreductive surgery, including right hemicolectomy
and wedge resection of the liver, was then performed, and
no gross residual tumor remained. Histologically, the tumors
in the liver and on the peritoneal surface were confirmed as
malignant GIST consisting of spindle cells that exhibited
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Fig. 1. Post-contrast CT. About a 1.3 cm round focal lesion with low attenuation
density (arrow) showing a target-like appearance of mild contrast enhancement
with centrally non-enhancing necrotic area in the right lobe of the liver suggests a
single hepatic metastasis. 
Fig. 2. The histologic picture of duodenal tumor shows the bundles of spindle
cells (hematoxylin and eosin staining).
Fig. 3. Four-month follow-up CT shows a newly developed metastasis (arrow) in
the posterior segment of right lobe of the liver.  
Fig. 4. Post-contrast CT. About 3 cm low attenuation density lesion (arrowheads)
in left lobe of the liver suggests a metastatic malignancy.  
diffuse immunohistochemistry staining for c-kit (Figs. 5 and
6). However, the tumor cells were not stained for smooth
muscle actin and the S-100 protein. The patient recovered
uneventfully, and he started chemotherapy with imatinib
mesylate at a dosage of 400 mg daily after two weeks of
surgery. Five years later, the patient was treated with imatinib
mesylate and doing well with no evidence of recurrence. 
Until recently, the origin and the pathobiology of GISTs
were not fully understood, leaving the categorization of
such tumors as enigmatic, unpredictable, and rare. As there
is no specific staging system or grading for the malignancy
of GISTs, it is difficult to predict the metastatic potential for
the primary GIST.7 GISTs, except those less than 1.0 cm in
size, can exhibit malignant behavior, with the tumor size
and mitotic index serving as the most important prognostic
factors.8
In primary, localized GISTs, complete resection of the
tumors is the treatment of choice.1 However, 20 to 25% of
gastric stromal tumors and 40 to 50% of small intestinal
stromal tumors undergo metastasis, and more than half of
patients experience tumor recurrence during the course of
their disease.2 Thus, in the treatment of recurrent or metastatic
GISTs, surgery alone is usually not sufficient. 
Since 2000, there has been a shift in paradigm for the
treatment of GIST, and Kit/PDGFRA tyrosine kinase
inhibitors such as imatinib have been applied in the treat-
ment of unresectable or recurrent GISTs. This oral therapy
has demonstrated good response in the majority of patients
and has has emerged as the gold standard treatment for
patients with metastatic GISTs.1 However, long-term success
is limited due to the development of imatinib resistance via
secondary mutations or clonal selection.9-13 Other inhibitors
of Kit/PDGFRA receptors or downstream signaling mole-
cules targets, such as protein kinase theta and tyrosine
kinase inhibitors of VEGFRs, have been utilized in cases
where imatinib has failed.14,15
Although there are several reports of combination therapy
of imatinib with surgery for the advanced GIST with
metastases, most of the studies used imatinib neoadjuvantly,
and the surgery was performed after the reduction of tumor
burden by imatinib therapy. However, we performed the
cytoreductive surgery first and then started the imatinib
therapy, because complete pathological responses are rare
with imatinib therapy alone, and cytoreductive surgery
could lessen the risk of recurrence by removing potentially
resistant clones. 
We tried to complete cytoreductive surgery in two cases
of recurrent GIST. The two patients received oral imatinib
therapy after cytoreductive surgery, and revealed no residual
disease for a long-term period of time. Although more studies
are needed to confirm whether cytoreductive surgery is
additive to imatinib treatment, our results were very encour-
aging in this regard. Therefore, in patients with far advanced
or recurring GISTs, improved survival could be expected
by imatinib oral therapy after removal of tumors as much as
possible. 
In far advanced or severely metastasized patients, neoad-
juvant therapy commonly enables curative surgical resection.
Indeed, neoadjuvant therapy with imatinib for treatment of
malignant GISTs is able to increase the rate of complete
cytoreductive surgery. There are several reports of neoad-
juvant imatinib chemotherapy therapy used to treat primary
unresectable GISTs, allowing them to be resected comple-
tely. However, resistance is commonly observed after neo-
adjuvant imatinib therapy, and surgical intervention should
always be considered in neoadjuvant therapy group, since
the duration of neoadjuvant chemotherapy and an optimal
time for surgery are decisive factors.16
Even after complete resection of primary tumor, more
than half of patients experience recurrence of tumors. And
the first site of recurrence is usually limited in the abdomen,
even though recurrent GISTs have a multifocal nature.17
However, complete resection can be achieved only in less
than half of patients. Thus, patients should be followed up
regularly from early period after resection of the primary
tumor, because an early detection of metastasis could
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DISCUSSION
Fig. 5. The mesenteric tumors are composed of spindle cells (hematoxylin and
eosin staining). 
Fig. 6. Immunohistochemically, the cytoplasm of tumor cells tests diffusely
positive for c-kit.
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possibly increase complete cytoreduction of the recurrent
tumor burden. Furthermore, this complete cytoreduction
followed by imatinib therapy might be able to improve the
survival of patients with recurrent GISTs. 
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